Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 05:48 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT00111540 · Registry updated: 2015-02-23

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2002-11. Completion: 2006-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta, exendin-4, AC2993

Where the study takes place — 60 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Research Site
Birmingham, Alabama, United States
Site recruitment: Not reported
Research Site
Anaheim, California, United States
Site recruitment: Not reported
Research Site
Bellflower, California, United States
Site recruitment: Not reported
Research Site
Burlingame, California, United States
Site recruitment: Not reported
Research Site
Chula Vista, California, United States
Site recruitment: Not reported
Research Site
Concord, California, United States
Site recruitment: Not reported
Research Site
Encino, California, United States
Site recruitment: Not reported
Research Site
Fremont, California, United States
Site recruitment: Not reported
Research Site
La Jolla, California, United States
Site recruitment: Not reported
Research Site
Los Gatos, California, United States
Site recruitment: Not reported
Research Site
Moreno Valley, California, United States
Site recruitment: Not reported
Research Site
Redwood City, California, United States
Site recruitment: Not reported
Research Site
San Mateo, California, United States
Site recruitment: Not reported
Research Site
Walnut Creek, California, United States
Site recruitment: Not reported
Research Site
Aurora, Colorado, United States
Site recruitment: Not reported
Research Site
Denver, Colorado, United States
Site recruitment: Not reported
Research Site
Gainesville, Florida, United States
Site recruitment: Not reported
Research Site
Jacksonville, Florida, United States
Site recruitment: Not reported
Research Site
Largo, Florida, United States
Site recruitment: Not reported
Research Site
Maitland, Florida, United States
Site recruitment: Not reported
Research Site
Miami, Florida, United States
Site recruitment: Not reported
Research Site
Ocala, Florida, United States
Site recruitment: Not reported
Research Site
Blairsville, Georgia, United States
Site recruitment: Not reported
Research Site
Honolulu, Hawaii, United States
Site recruitment: Not reported
Research Site
Chicago, Illinois, United States
Site recruitment: Not reported
Research Site
Indianapolis, Indiana, United States
Site recruitment: Not reported
Research Site
Lexington, Kentucky, United States
Site recruitment: Not reported
Research Site
Covington, Louisiana, United States
Site recruitment: Not reported
Research Site
New Orleans, Louisiana, United States
Site recruitment: Not reported
Research Site
Slidell, Louisiana, United States
Site recruitment: Not reported
Research Site
Detroit, Michigan, United States
Site recruitment: Not reported
Research Site
Edina, Minnesota, United States
Site recruitment: Not reported
Research Site
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Research Site
Gulfport, Mississippi, United States
Site recruitment: Not reported
Research Site
Picayune, Mississippi, United States
Site recruitment: Not reported
Research Site
Chesterfield, Missouri, United States
Site recruitment: Not reported
Research Site
St Louis, Missouri, United States
Site recruitment: Not reported
Research Site
Butte, Montana, United States
Site recruitment: Not reported
Research Site
Las Vegas, Nevada, United States
Site recruitment: Not reported
Research Site
New York, New York, United States
Site recruitment: Not reported
Research Site
Rochester, New York, United States
Site recruitment: Not reported
Research Site
Cary, North Carolina, United States
Site recruitment: Not reported
Research Site
Durham, North Carolina, United States
Site recruitment: Not reported
Research Site
Columbus, Ohio, United States
Site recruitment: Not reported
Research Site
Marion, Ohio, United States
Site recruitment: Not reported
Research Site
Maumee, Ohio, United States
Site recruitment: Not reported
Research Site
Mentor, Ohio, United States
Site recruitment: Not reported
Research Site
Clinton, Oklahoma, United States
Site recruitment: Not reported
Research Site
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Research Site
Medford, Oregon, United States
Site recruitment: Not reported
Research Site
Portland, Oregon, United States
Site recruitment: Not reported
Research Site
Camp Hill, Pennsylvania, United States
Site recruitment: Not reported
Research Site
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Research Site
Dallas, Texas, United States
Site recruitment: Not reported
Research Site
Houston, Texas, United States
Site recruitment: Not reported
Research Site
Midland, Texas, United States
Site recruitment: Not reported
Research Site
San Antonio, Texas, United States
Site recruitment: Not reported
Research Site
Salt Lake City, Utah, United States
Site recruitment: Not reported
Research Site
Olympia, Washington, United States
Site recruitment: Not reported
Research Site
Spokane, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT00382239 · Registry updated: 2015-02-23

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: Japan
Registry dates and results: Start: 2006-09. Completion: 2007-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (LY2148568) (drug) — also listed as: Byetta
exenatide (LY2148568) (drug) — also listed as: Byetta
exenatide (LY2148568) (drug) — also listed as: Byetta
Placebo (drug)

Where the study takes place — 14 listed sites

Research Site
Fukuoka, Japan
Site recruitment: Not reported
Research Site
Fukushima, Japan
Site recruitment: Not reported
Research Site
Gunma, Japan
Site recruitment: Not reported
Research Site
Hiroshima, Japan
Site recruitment: Not reported
Research Site
Hyōgo, Japan
Site recruitment: Not reported
Research Site
Ibaraki, Japan
Site recruitment: Not reported
Research Site
Kanagawa, Japan
Site recruitment: Not reported
Research Site
Kumamoto, Japan
Site recruitment: Not reported
Research Site
Kyoto, Japan
Site recruitment: Not reported
Research Site
Nagano, Japan
Site recruitment: Not reported
Research Site
Okayama, Japan
Site recruitment: Not reported
Research Site
Osaka, Japan
Site recruitment: Not reported
Research Site
Ōita, Japan
Site recruitment: Not reported
Research Site
Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT00085969 · Registry updated: 2015-02-23

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2003-09. Completion: 2004-01 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo 0.04 mL twice daily (drug)
Placebo 0.04 mL once daily (drug)
Placebo 0.08 mL once daily (drug)
B - Exenatide 10 mcg twice daily (drug) — also listed as: ACC2993, synthetic exendin-4
C - Exenatide 10 mcg once daily (drug) — also listed as: ACC2993, synthetic exendin-4
Exenatide 20 mcg once daily (drug) — also listed as: ACC2993, synthetic exendin-4

Where the study takes place — 23 listed sites

The Whittier Institute for Diabetes
La Jolla, California, United States
Site recruitment: Not reported
VA Medical Center
San Diego, California, United States
Site recruitment: Not reported
MedStar Research Institute
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Internal Medicine Associates, Department of Research
Fort Myers, Florida, United States
Site recruitment: Not reported
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
Site recruitment: Not reported
Innovative Research of West Florida
Largo, Florida, United States
Site recruitment: Not reported
Henry Ford Health System
Detroit, Michigan, United States
Site recruitment: Not reported
Grand Rapids Associated Internists
Grand Rapids, Michigan, United States
Site recruitment: Not reported
Radiant Research, Inc.
St Louis, Missouri, United States
Site recruitment: Not reported
Internal Medicine Associates
Bozeman, Montana, United States
Site recruitment: Not reported
Mercury Street Medical Group
Butte, Montana, United States
Site recruitment: Not reported
Lovelace Scientific Resources
Las Vegas, Nevada, United States
Site recruitment: Not reported
Rochester Clinical Research, Inc.
Rochester, New York, United States
Site recruitment: Not reported
Metrolina Medical Research
Charlotte, North Carolina, United States
Site recruitment: Not reported
Piedmont Medical Research Associates
Winston-Salem, North Carolina, United States
Site recruitment: Not reported
Radiant Research
Columbus, Ohio, United States
Site recruitment: Not reported
Smith Clinic Research
Marion, Ohio, United States
Site recruitment: Not reported
Radiant Research
Portland, Oregon, United States
Site recruitment: Not reported
Philadelphia Health Associates - Adult Medicine
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Diabetes and Glandular Disease Research Associates
San Antonio, Texas, United States
Site recruitment: Not reported
S.A.M. Clinical Research Center
San Antonio, Texas, United States
Site recruitment: Not reported
McGuire VA Medical Center
Richmond, Virginia, United States
Site recruitment: Not reported
Rockwood Clinic
Spokane, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Safety and Efficacy of Exenatide as Monotherapy

ClinicalTrials.gov · NCT00381342 · Registry updated: 2015-02-23

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: India · Puerto Rico · Romania · Russia · United States
Registry dates and results: Start: 2006-09. Completion: 2007-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta
exenatide (drug) — also listed as: Byetta
placebo (drug)

Where the study takes place — 19 listed sites

Research Site
Idaho Falls, Idaho, United States
Site recruitment: Not reported
Research Site
Indianapolis, Indiana, United States
Site recruitment: Not reported
Research Site
Aligarh, India
Site recruitment: Not reported
Research Site
Bangalore, India
Site recruitment: Not reported
Research Site
Chennai, India
Site recruitment: Not reported
Research Site
Indore, India
Site recruitment: Not reported
Research Site
Karnāl, India
Site recruitment: Not reported
Research Site
New Delhi, India
Site recruitment: Not reported
Research Site
Vellore, India
Site recruitment: Not reported
Research Site
Manati, Puerto Rico
Site recruitment: Not reported
Research Site
San Juan, Puerto Rico
Site recruitment: Not reported
Research Site
Alba Iulia, Romania
Site recruitment: Not reported
Research Site
Baia Mare, Romania
Site recruitment: Not reported
Research Site
Bucharest, Romania
Site recruitment: Not reported
Research Site
Galati, Romania
Site recruitment: Not reported
Research Site
Oradea, Romania
Site recruitment: Not reported
Research Site
Târgu Mureş, Romania
Site recruitment: Not reported
Research Site
Moscow, Russia
Site recruitment: Not reported
Research Site
Saint Petersburg, Russia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT00517283 · Registry updated: 2015-02-23

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2005-01. Completion: 2005-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide and placebo (drug) — also listed as: Byetta, AC2993, synthetic exendin-4
Exenatide and placebo (drug) — also listed as: Byetta, AC2993, synthetic exendin-4
Exenatide and placebo (drug) — also listed as: Byetta, AC2993, synthetic exendin-4

Where the study takes place — 1 listed sites

Research Site
Nottingham, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

ClinicalTrials.gov · NCT00044668 · Registry updated: 2015-02-20

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: AstraZeneca
Countries with listed sites: Hungary
Registry dates and results: Start: 2002-08. Completion: 2005-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AC2993 (drug) — also listed as: synthetic exendin-4

Where the study takes place — 3 listed sites

Diagnostic Units Hungary Kft.
Budapest, Hungary, Hungary
Site recruitment: Not reported
Peterfy Teaching Hospital
Budapest, Hungary, Hungary
Site recruitment: Not reported
Uzsoki Street Municipal Hospital
Budapest, Hungary, Hungary
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT00044694 · Registry updated: 2015-02-20

Condition / research focus: Diabetes Mellitus, Non-Insulin-Dependent
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2002-08. Completion: 2003-05 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo 0.01 mL (drug)
Placebo 0.02 mL (drug)
Placebo 0.03 mL (drug)
Placebo 0.04 mL (drug)
AC2993 2.5 mcg (drug) — also listed as: synthetic exendin-4
AC2993 5.0 mcg (drug) — also listed as: synthetic exendin-4
AC2993 7.5 mcg (drug) — also listed as: synthetic exendin-4
AC2993 10.0 mcg (drug) — also listed as: synthetic exendin-4

Where the study takes place — 33 listed sites

Innovative Clinical Trials
Birmingham, Alabama, United States
Site recruitment: Not reported
Healthsouth Clinical Research
Birmingham, Alabama, United States
Site recruitment: Not reported
Endocrinology Clinic of O.C.
Anaheim, California, United States
Site recruitment: Not reported
Pioneer Medical Group
Bellflower, California, United States
Site recruitment: Not reported
International Clinical Research Network
Chula Vista, California, United States
Site recruitment: Not reported
Bautista Research and Medical Clinic
Fresno, California, United States
Site recruitment: Not reported
Whittier Institute for Diabetes
La Jolla, California, United States
Site recruitment: Not reported
Richard Cherlin, M.D.
Los Gatos, California, United States
Site recruitment: Not reported
Dr. Martinez Medical Clinic
Moreno Valley, California, United States
Site recruitment: Not reported
Anshutz Outpatient Pavilion
Aurora, Colorado, United States
Site recruitment: Not reported
Diagnostic Clinic
Clearwater, Florida, United States
Site recruitment: Not reported
Radiant Research-Gainsville
Gainsville, Florida, United States
Site recruitment: Not reported
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
Site recruitment: Not reported
Radiant Research-Pinellas Park
Pinellas Park, Florida, United States
Site recruitment: Not reported
Clinical Research Group of North Georgia
Blairsville, Georgia, United States
Site recruitment: Not reported
East-West Medical Research Institute
Honolulu, Hawaii, United States
Site recruitment: Not reported
Radiant Research-Honolulu
Honolulu, Hawaii, United States
Site recruitment: Not reported
Radiant Research-Boise
Boise, Idaho, United States
Site recruitment: Not reported
Cedar-Crosse Research Center
Chicago, Illinois, United States
Site recruitment: Not reported
Northshore Medical Research, LLC
Covington, Louisiana, United States
Site recruitment: Not reported
Medical Research Institute
Slidell, Louisiana, United States
Site recruitment: Not reported
Melvin Kramer, MD
Concord, Massachusetts, United States
Site recruitment: Not reported
Radiant Research-Edina
Edina, Minnesota, United States
Site recruitment: Not reported
Mississippi Medical Research, LLC
Gulfport, Mississippi, United States
Site recruitment: Not reported
The Center for Pharmaceutical Research
Kansas City, Missouri, United States
Site recruitment: Not reported
Innovative Health Research
Las Vegas, Nevada, United States
Site recruitment: Not reported
Carolina Advanced Research
Cary, North Carolina, United States
Site recruitment: Not reported
Fallen Timbers Internal Medicine, LLC
Maumee, Ohio, United States
Site recruitment: Not reported
Millenium Research
Benbrook, Texas, United States
Site recruitment: Not reported
Healthsouth Clinical Research
DeSoto, Texas, United States
Site recruitment: Not reported
Baylor College of Medicine/Clinical Studies Unit
Houston, Texas, United States
Site recruitment: Not reported
Diabetes Center of the Southwest
Midland, Texas, United States
Site recruitment: Not reported
Utah Diabetes Center at the University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Safety and Efficacy of YH14617 in Diabetes Mellitus

ClinicalTrials.gov · NCT01507038 · Registry updated: 2015-02-18

Condition / research focus: Diabetes Mellitus
Sponsor: Yuhan Corporation
Countries with listed sites: South Korea
Registry dates and results: Start: 2011-12. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

YH14617 (drug)
YH14617 (drug)
YH14617 (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Yuhan
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Autoinjector Device Assessment Study

ClinicalTrials.gov · NCT02349802 · Registry updated: 2015-02-02

Condition / research focus: Healthy Subjects
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Auto-injector with exenatide suspension (drug)
Syringe with exenatide suspension (drug)

Where the study takes place — 2 listed sites

Research Site
Tempe, Arizona, United States
Site recruitment: Not reported
Research Site
Lincoln, Nebraska, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients

ClinicalTrials.gov · NCT02344641 · Registry updated: 2015-01-27

Condition / research focus: Type 2 Diabetes Mellitus; Heart Failure
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-01. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study in Participants With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT01064687 · Registry updated: 2015-01-26

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Eli Lilly and Company
Countries with listed sites: Argentina · Mexico · Puerto Rico · United States
Registry dates and results: Start: 2010-02. Completion: 2012-05 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LY2189265 (drug) — also listed as: Dulaglutide
Exenatide (drug)
Placebo (drug)
Metformin (drug)
Pioglitazone (drug)

Where the study takes place — 89 listed sites

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Goodyear, Arizona, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Phoenix, Arizona, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cathedral City, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Concord, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fresno, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Greenbrae, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Lancaster, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mission Hills, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Monterey, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
National City, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Oceanside, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Paramount, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Roseville, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Ramon, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tustin, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
New Britain, Connecticut, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fort Lauderdale, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hollywood, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Orlando, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Pembroke Pines, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
West Palm Beach, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Atlanta, Georgia, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Honolulu, Hawaii, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Boise, Idaho, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Idaho Falls, Idaho, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Meridian, Idaho, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Crystal Lake, Illinois, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Peoria, Illinois, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Vincennes, Indiana, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Topeka, Kansas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Madisonville, Kentucky, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
New Orleans, Louisiana, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bangor, Maine, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Biddeford, Maine, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Elkridge, Maryland, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bloomfield Hills, Michigan, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Flint, Michigan, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
St Louis, Missouri, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nashua, New Hampshire, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Toms River, New Jersey, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Albany, New York, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Flushing, New York, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Syracuse, New York, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Asheville, North Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cary, North Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Durham, North Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Morehead City, North Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cincinnati, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cleveland, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Columbus, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dayton, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Delaware, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Perrysburg, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bend, Oregon, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Corvallis, Oregon, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Eugene, Oregon, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Beaver, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Danville, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Levittown, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Wilkes-Barre, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Charleston, South Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Greenville, South Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Greer, South Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Myrtle Beach, South Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Memphis, Tennessee, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Arlington, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Austin, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Corpus Christi, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dallas, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
El Paso, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Antonio, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Schertz, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ogden, Utah, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
St. George, Utah, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
West Jordan, Utah, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Spokane, Washington, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tacoma, Washington, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Buenos Aires, Argentina
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Guadalajara, Mexico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mexico City, Mexico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Monterrey, Mexico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Caguas, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hato Rey, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Manati, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ponce, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San German, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Juan, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Yabucoa, Puerto Rico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Bioenergetic Alterations After Exenatide Administration

ClinicalTrials.gov · NCT00623545 · Registry updated: 2015-01-09

Condition / research focus: Healthy
Sponsor: University of Wisconsin, Madison
Countries with listed sites: United States
Registry dates and results: Start: 2008-01. Completion: 2010-04 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

Univ Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

ClinicalTrials.gov · NCT00937079 · Registry updated: 2015-01-09

Condition / research focus: Hyperinsulinism; Hypoglycemia; Insulinoma
Sponsor: University Hospital, Basel, Switzerland
Countries with listed sites: Switzerland
Registry dates and results: Start: 2007-11. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

111In-exendin-4 imaging (other)

Where the study takes place — 1 listed sites

University Hospital Basel, Institute of Nuclear Medicine
Basel, Canton of Basel-City, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

ClinicalTrials.gov · NCT01825148 · Registry updated: 2014-12-02

Condition / research focus: Type 1 Diabetes
Sponsor: Radboud University Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2012-12. Completion: 2014-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

radiolabeled Exendin (other)

Where the study takes place — 1 listed sites

Radboud University Nijmegen Medical Center
Nijmegen, Gelderland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

ClinicalTrials.gov · NCT00736229 · Registry updated: 2014-11-20

Condition / research focus: Hyperglycemia; Acute Coronary Syndromes; Myocardial Infarction
Sponsor: Saint Luke's Health System
Countries with listed sites: United States
Registry dates and results: Start: 2008-08. Completion: 2012-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

Mid America Heart Institute Saint Luke's Health System
Kansas City, Missouri, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Exenatide in Extreme Pediatric Obesity

ClinicalTrials.gov · NCT01237197 · Registry updated: 2014-09-12

Condition / research focus: Obesity
Sponsor: University of Minnesota
Countries with listed sites: United States
Registry dates and results: Start: 2010-10. Completion: 2012-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Placebo (drug) — also listed as: Sugar pill

Where the study takes place — 2 listed sites

University of Minnesota
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Children's Hospitals and Clinics of Minnesota
Saint Paul, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Glucagon-like Peptide (GLP) Utilization and Safety

ClinicalTrials.gov · NCT01767389 · Registry updated: 2014-08-04

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: GlaxoSmithKline
Countries with listed sites: No country reported
Registry dates and results: Start: 2012-09. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

The GLP-1 receptor agonist users (other)
DPP-4 inhibitor users (other)
Other ADA users (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine

ClinicalTrials.gov · NCT01602913 · Registry updated: 2014-07-02

Condition / research focus: Depression, Postpartum
Sponsor: GlaxoSmithKline
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-12. Completion: 2012-05 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pravastatin alone (drug)
Paroxetine alone (drug)
Pravastatin and paroxetine combined (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

ClinicalTrials.gov · NCT01181986 · Registry updated: 2014-05-20

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Carl T. Hayden VA Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2010-08. Completion: 2012-12 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide SC (drug) — also listed as: Byetta, exendin-4
Exenatide IV (drug) — also listed as: exendin-4, Byetta
Placebo SC (drug) — also listed as: placebo
Exendin-9 (drug) — also listed as: exendin-(9-39)
Placebo IV (drug) — also listed as: placebo

Where the study takes place — 1 listed sites

Phoenix VA Medical Center
Phoenix, Arizona, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

ClinicalTrials.gov · NCT02129985 · Registry updated: 2014-05-02

Condition / research focus: Type 2 Diabetes
Sponsor: xiaolong zhao
Countries with listed sites: China
Registry dates and results: Start: 2014-02. Completion: 2015-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: GLP-1 receptor agonist
Metformin (drug) — also listed as: Glucophage

Where the study takes place — 1 listed sites

Xiaolong Zhao
Jingan, Shanghai Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 05:48 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT00111540 · Registry updated: 2015-02-23

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2002-11. Completion: 2006-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta, exendin-4, AC2993

Where the study takes place — 60 listed sites

Research Site
Birmingham, Alabama, United States
Site recruitment: Not reported
Research Site
Anaheim, California, United States
Site recruitment: Not reported
Research Site
Bellflower, California, United States
Site recruitment: Not reported
Research Site
Burlingame, California, United States
Site recruitment: Not reported
Research Site
Chula Vista, California, United States
Site recruitment: Not reported
Research Site
Concord, California, United States
Site recruitment: Not reported
Research Site
Encino, California, United States
Site recruitment: Not reported
Research Site
Fremont, California, United States
Site recruitment: Not reported
Research Site
La Jolla, California, United States
Site recruitment: Not reported
Research Site
Los Gatos, California, United States
Site recruitment: Not reported
Research Site
Moreno Valley, California, United States
Site recruitment: Not reported
Research Site
Redwood City, California, United States
Site recruitment: Not reported
Research Site
San Mateo, California, United States
Site recruitment: Not reported
Research Site
Walnut Creek, California, United States
Site recruitment: Not reported
Research Site
Aurora, Colorado, United States
Site recruitment: Not reported
Research Site
Denver, Colorado, United States
Site recruitment: Not reported
Research Site
Gainesville, Florida, United States
Site recruitment: Not reported
Research Site
Jacksonville, Florida, United States
Site recruitment: Not reported
Research Site
Largo, Florida, United States
Site recruitment: Not reported
Research Site
Maitland, Florida, United States
Site recruitment: Not reported
Research Site
Miami, Florida, United States
Site recruitment: Not reported
Research Site
Ocala, Florida, United States
Site recruitment: Not reported
Research Site
Blairsville, Georgia, United States
Site recruitment: Not reported
Research Site
Honolulu, Hawaii, United States
Site recruitment: Not reported
Research Site
Chicago, Illinois, United States
Site recruitment: Not reported
Research Site
Indianapolis, Indiana, United States
Site recruitment: Not reported
Research Site
Lexington, Kentucky, United States
Site recruitment: Not reported
Research Site
Covington, Louisiana, United States
Site recruitment: Not reported
Research Site
New Orleans, Louisiana, United States
Site recruitment: Not reported
Research Site
Slidell, Louisiana, United States
Site recruitment: Not reported
Research Site
Detroit, Michigan, United States
Site recruitment: Not reported
Research Site
Edina, Minnesota, United States
Site recruitment: Not reported
Research Site
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Research Site
Gulfport, Mississippi, United States
Site recruitment: Not reported
Research Site
Picayune, Mississippi, United States
Site recruitment: Not reported
Research Site
Chesterfield, Missouri, United States
Site recruitment: Not reported
Research Site
St Louis, Missouri, United States
Site recruitment: Not reported
Research Site
Butte, Montana, United States
Site recruitment: Not reported
Research Site
Las Vegas, Nevada, United States
Site recruitment: Not reported
Research Site
New York, New York, United States
Site recruitment: Not reported
Research Site
Rochester, New York, United States
Site recruitment: Not reported
Research Site
Cary, North Carolina, United States
Site recruitment: Not reported
Research Site
Durham, North Carolina, United States
Site recruitment: Not reported
Research Site
Columbus, Ohio, United States
Site recruitment: Not reported
Research Site
Marion, Ohio, United States
Site recruitment: Not reported
Research Site
Maumee, Ohio, United States
Site recruitment: Not reported
Research Site
Mentor, Ohio, United States
Site recruitment: Not reported
Research Site
Clinton, Oklahoma, United States
Site recruitment: Not reported
Research Site
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Research Site
Medford, Oregon, United States
Site recruitment: Not reported
Research Site
Portland, Oregon, United States
Site recruitment: Not reported
Research Site
Camp Hill, Pennsylvania, United States
Site recruitment: Not reported
Research Site
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Research Site
Dallas, Texas, United States
Site recruitment: Not reported
Research Site
Houston, Texas, United States
Site recruitment: Not reported
Research Site
Midland, Texas, United States
Site recruitment: Not reported
Research Site
San Antonio, Texas, United States
Site recruitment: Not reported
Research Site
Salt Lake City, Utah, United States
Site recruitment: Not reported
Research Site
Olympia, Washington, United States
Site recruitment: Not reported
Research Site
Spokane, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT00382239 · Registry updated: 2015-02-23

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: Japan
Registry dates and results: Start: 2006-09. Completion: 2007-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (LY2148568) (drug) — also listed as: Byetta
exenatide (LY2148568) (drug) — also listed as: Byetta
exenatide (LY2148568) (drug) — also listed as: Byetta
Placebo (drug)

Where the study takes place — 14 listed sites

Research Site
Fukuoka, Japan
Site recruitment: Not reported
Research Site
Fukushima, Japan
Site recruitment: Not reported
Research Site
Gunma, Japan
Site recruitment: Not reported
Research Site
Hiroshima, Japan
Site recruitment: Not reported
Research Site
Hyōgo, Japan
Site recruitment: Not reported
Research Site
Ibaraki, Japan
Site recruitment: Not reported
Research Site
Kanagawa, Japan
Site recruitment: Not reported
Research Site
Kumamoto, Japan
Site recruitment: Not reported
Research Site
Kyoto, Japan
Site recruitment: Not reported
Research Site
Nagano, Japan
Site recruitment: Not reported
Research Site
Okayama, Japan
Site recruitment: Not reported
Research Site
Osaka, Japan
Site recruitment: Not reported
Research Site
Ōita, Japan
Site recruitment: Not reported
Research Site
Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT00085969 · Registry updated: 2015-02-23

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2003-09. Completion: 2004-01 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo 0.04 mL twice daily (drug)
Placebo 0.04 mL once daily (drug)
Placebo 0.08 mL once daily (drug)
B - Exenatide 10 mcg twice daily (drug) — also listed as: ACC2993, synthetic exendin-4
C - Exenatide 10 mcg once daily (drug) — also listed as: ACC2993, synthetic exendin-4
Exenatide 20 mcg once daily (drug) — also listed as: ACC2993, synthetic exendin-4

Where the study takes place — 23 listed sites

The Whittier Institute for Diabetes
La Jolla, California, United States
Site recruitment: Not reported
VA Medical Center
San Diego, California, United States
Site recruitment: Not reported
MedStar Research Institute
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Internal Medicine Associates, Department of Research
Fort Myers, Florida, United States
Site recruitment: Not reported
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
Site recruitment: Not reported
Innovative Research of West Florida
Largo, Florida, United States
Site recruitment: Not reported
Henry Ford Health System
Detroit, Michigan, United States
Site recruitment: Not reported
Grand Rapids Associated Internists
Grand Rapids, Michigan, United States
Site recruitment: Not reported
Radiant Research, Inc.
St Louis, Missouri, United States
Site recruitment: Not reported
Internal Medicine Associates
Bozeman, Montana, United States
Site recruitment: Not reported
Mercury Street Medical Group
Butte, Montana, United States
Site recruitment: Not reported
Lovelace Scientific Resources
Las Vegas, Nevada, United States
Site recruitment: Not reported
Rochester Clinical Research, Inc.
Rochester, New York, United States
Site recruitment: Not reported
Metrolina Medical Research
Charlotte, North Carolina, United States
Site recruitment: Not reported
Piedmont Medical Research Associates
Winston-Salem, North Carolina, United States
Site recruitment: Not reported
Radiant Research
Columbus, Ohio, United States
Site recruitment: Not reported
Smith Clinic Research
Marion, Ohio, United States
Site recruitment: Not reported
Radiant Research
Portland, Oregon, United States
Site recruitment: Not reported
Philadelphia Health Associates - Adult Medicine
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Diabetes and Glandular Disease Research Associates
San Antonio, Texas, United States
Site recruitment: Not reported
S.A.M. Clinical Research Center
San Antonio, Texas, United States
Site recruitment: Not reported
McGuire VA Medical Center
Richmond, Virginia, United States
Site recruitment: Not reported
Rockwood Clinic
Spokane, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Safety and Efficacy of Exenatide as Monotherapy

ClinicalTrials.gov · NCT00381342 · Registry updated: 2015-02-23

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: India · Puerto Rico · Romania · Russia · United States
Registry dates and results: Start: 2006-09. Completion: 2007-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta
exenatide (drug) — also listed as: Byetta
placebo (drug)

Where the study takes place — 19 listed sites

Research Site
Idaho Falls, Idaho, United States
Site recruitment: Not reported
Research Site
Indianapolis, Indiana, United States
Site recruitment: Not reported
Research Site
Aligarh, India
Site recruitment: Not reported
Research Site
Bangalore, India
Site recruitment: Not reported
Research Site
Chennai, India
Site recruitment: Not reported
Research Site
Indore, India
Site recruitment: Not reported
Research Site
Karnāl, India
Site recruitment: Not reported
Research Site
New Delhi, India
Site recruitment: Not reported
Research Site
Vellore, India
Site recruitment: Not reported
Research Site
Manati, Puerto Rico
Site recruitment: Not reported
Research Site
San Juan, Puerto Rico
Site recruitment: Not reported
Research Site
Alba Iulia, Romania
Site recruitment: Not reported
Research Site
Baia Mare, Romania
Site recruitment: Not reported
Research Site
Bucharest, Romania
Site recruitment: Not reported
Research Site
Galati, Romania
Site recruitment: Not reported
Research Site
Oradea, Romania
Site recruitment: Not reported
Research Site
Târgu Mureş, Romania
Site recruitment: Not reported
Research Site
Moscow, Russia
Site recruitment: Not reported
Research Site
Saint Petersburg, Russia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT00517283 · Registry updated: 2015-02-23

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2005-01. Completion: 2005-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide and placebo (drug) — also listed as: Byetta, AC2993, synthetic exendin-4
Exenatide and placebo (drug) — also listed as: Byetta, AC2993, synthetic exendin-4
Exenatide and placebo (drug) — also listed as: Byetta, AC2993, synthetic exendin-4

Where the study takes place — 1 listed sites

Research Site
Nottingham, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

ClinicalTrials.gov · NCT00044668 · Registry updated: 2015-02-20

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: AstraZeneca
Countries with listed sites: Hungary
Registry dates and results: Start: 2002-08. Completion: 2005-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AC2993 (drug) — also listed as: synthetic exendin-4

Where the study takes place — 3 listed sites

Diagnostic Units Hungary Kft.
Budapest, Hungary, Hungary
Site recruitment: Not reported
Peterfy Teaching Hospital
Budapest, Hungary, Hungary
Site recruitment: Not reported
Uzsoki Street Municipal Hospital
Budapest, Hungary, Hungary
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT00044694 · Registry updated: 2015-02-20

Condition / research focus: Diabetes Mellitus, Non-Insulin-Dependent
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2002-08. Completion: 2003-05 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo 0.01 mL (drug)
Placebo 0.02 mL (drug)
Placebo 0.03 mL (drug)
Placebo 0.04 mL (drug)
AC2993 2.5 mcg (drug) — also listed as: synthetic exendin-4
AC2993 5.0 mcg (drug) — also listed as: synthetic exendin-4
AC2993 7.5 mcg (drug) — also listed as: synthetic exendin-4
AC2993 10.0 mcg (drug) — also listed as: synthetic exendin-4

Where the study takes place — 33 listed sites

Innovative Clinical Trials
Birmingham, Alabama, United States
Site recruitment: Not reported
Healthsouth Clinical Research
Birmingham, Alabama, United States
Site recruitment: Not reported
Endocrinology Clinic of O.C.
Anaheim, California, United States
Site recruitment: Not reported
Pioneer Medical Group
Bellflower, California, United States
Site recruitment: Not reported
International Clinical Research Network
Chula Vista, California, United States
Site recruitment: Not reported
Bautista Research and Medical Clinic
Fresno, California, United States
Site recruitment: Not reported
Whittier Institute for Diabetes
La Jolla, California, United States
Site recruitment: Not reported
Richard Cherlin, M.D.
Los Gatos, California, United States
Site recruitment: Not reported
Dr. Martinez Medical Clinic
Moreno Valley, California, United States
Site recruitment: Not reported
Anshutz Outpatient Pavilion
Aurora, Colorado, United States
Site recruitment: Not reported
Diagnostic Clinic
Clearwater, Florida, United States
Site recruitment: Not reported
Radiant Research-Gainsville
Gainsville, Florida, United States
Site recruitment: Not reported
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
Site recruitment: Not reported
Radiant Research-Pinellas Park
Pinellas Park, Florida, United States
Site recruitment: Not reported
Clinical Research Group of North Georgia
Blairsville, Georgia, United States
Site recruitment: Not reported
East-West Medical Research Institute
Honolulu, Hawaii, United States
Site recruitment: Not reported
Radiant Research-Honolulu
Honolulu, Hawaii, United States
Site recruitment: Not reported
Radiant Research-Boise
Boise, Idaho, United States
Site recruitment: Not reported
Cedar-Crosse Research Center
Chicago, Illinois, United States
Site recruitment: Not reported
Northshore Medical Research, LLC
Covington, Louisiana, United States
Site recruitment: Not reported
Medical Research Institute
Slidell, Louisiana, United States
Site recruitment: Not reported
Melvin Kramer, MD
Concord, Massachusetts, United States
Site recruitment: Not reported
Radiant Research-Edina
Edina, Minnesota, United States
Site recruitment: Not reported
Mississippi Medical Research, LLC
Gulfport, Mississippi, United States
Site recruitment: Not reported
The Center for Pharmaceutical Research
Kansas City, Missouri, United States
Site recruitment: Not reported
Innovative Health Research
Las Vegas, Nevada, United States
Site recruitment: Not reported
Carolina Advanced Research
Cary, North Carolina, United States
Site recruitment: Not reported
Fallen Timbers Internal Medicine, LLC
Maumee, Ohio, United States
Site recruitment: Not reported
Millenium Research
Benbrook, Texas, United States
Site recruitment: Not reported
Healthsouth Clinical Research
DeSoto, Texas, United States
Site recruitment: Not reported
Baylor College of Medicine/Clinical Studies Unit
Houston, Texas, United States
Site recruitment: Not reported
Diabetes Center of the Southwest
Midland, Texas, United States
Site recruitment: Not reported
Utah Diabetes Center at the University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Safety and Efficacy of YH14617 in Diabetes Mellitus

ClinicalTrials.gov · NCT01507038 · Registry updated: 2015-02-18

Condition / research focus: Diabetes Mellitus
Sponsor: Yuhan Corporation
Countries with listed sites: South Korea
Registry dates and results: Start: 2011-12. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

YH14617 (drug)
YH14617 (drug)
YH14617 (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Yuhan
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Autoinjector Device Assessment Study

ClinicalTrials.gov · NCT02349802 · Registry updated: 2015-02-02

Condition / research focus: Healthy Subjects
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Auto-injector with exenatide suspension (drug)
Syringe with exenatide suspension (drug)

Where the study takes place — 2 listed sites

Research Site
Tempe, Arizona, United States
Site recruitment: Not reported
Research Site
Lincoln, Nebraska, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients

ClinicalTrials.gov · NCT02344641 · Registry updated: 2015-01-27

Condition / research focus: Type 2 Diabetes Mellitus; Heart Failure
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-01. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study in Participants With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT01064687 · Registry updated: 2015-01-26

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Eli Lilly and Company
Countries with listed sites: Argentina · Mexico · Puerto Rico · United States
Registry dates and results: Start: 2010-02. Completion: 2012-05 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LY2189265 (drug) — also listed as: Dulaglutide
Exenatide (drug)
Placebo (drug)
Metformin (drug)
Pioglitazone (drug)

Where the study takes place — 89 listed sites

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Goodyear, Arizona, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Phoenix, Arizona, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cathedral City, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Concord, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fresno, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Greenbrae, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Lancaster, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mission Hills, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Monterey, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
National City, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Oceanside, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Paramount, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Roseville, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Ramon, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tustin, California, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
New Britain, Connecticut, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fort Lauderdale, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hollywood, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Orlando, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Pembroke Pines, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
West Palm Beach, Florida, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Atlanta, Georgia, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Honolulu, Hawaii, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Boise, Idaho, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Idaho Falls, Idaho, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Meridian, Idaho, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Crystal Lake, Illinois, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Peoria, Illinois, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Vincennes, Indiana, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Topeka, Kansas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Madisonville, Kentucky, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
New Orleans, Louisiana, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bangor, Maine, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Biddeford, Maine, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Elkridge, Maryland, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bloomfield Hills, Michigan, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Flint, Michigan, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
St Louis, Missouri, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nashua, New Hampshire, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Toms River, New Jersey, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Albany, New York, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Flushing, New York, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Syracuse, New York, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Asheville, North Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cary, North Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Durham, North Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Morehead City, North Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cincinnati, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cleveland, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Columbus, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dayton, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Delaware, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Perrysburg, Ohio, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bend, Oregon, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Corvallis, Oregon, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Eugene, Oregon, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Beaver, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Danville, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Levittown, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Wilkes-Barre, Pennsylvania, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Charleston, South Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Greenville, South Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Greer, South Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Myrtle Beach, South Carolina, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Memphis, Tennessee, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Arlington, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Austin, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Corpus Christi, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dallas, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
El Paso, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Antonio, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Schertz, Texas, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ogden, Utah, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
St. George, Utah, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
West Jordan, Utah, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Spokane, Washington, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tacoma, Washington, United States
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Buenos Aires, Argentina
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Guadalajara, Mexico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mexico City, Mexico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Monterrey, Mexico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Caguas, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hato Rey, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Manati, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ponce, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San German, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Juan, Puerto Rico
Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Yabucoa, Puerto Rico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Bioenergetic Alterations After Exenatide Administration

ClinicalTrials.gov · NCT00623545 · Registry updated: 2015-01-09

Condition / research focus: Healthy
Sponsor: University of Wisconsin, Madison
Countries with listed sites: United States
Registry dates and results: Start: 2008-01. Completion: 2010-04 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

Univ Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

ClinicalTrials.gov · NCT00937079 · Registry updated: 2015-01-09

Condition / research focus: Hyperinsulinism; Hypoglycemia; Insulinoma
Sponsor: University Hospital, Basel, Switzerland
Countries with listed sites: Switzerland
Registry dates and results: Start: 2007-11. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

111In-exendin-4 imaging (other)

Where the study takes place — 1 listed sites

University Hospital Basel, Institute of Nuclear Medicine
Basel, Canton of Basel-City, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

ClinicalTrials.gov · NCT01825148 · Registry updated: 2014-12-02

Condition / research focus: Type 1 Diabetes
Sponsor: Radboud University Medical Center
Countries with listed sites: Netherlands
Registry dates and results: Start: 2012-12. Completion: 2014-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

radiolabeled Exendin (other)

Where the study takes place — 1 listed sites

Radboud University Nijmegen Medical Center
Nijmegen, Gelderland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

ClinicalTrials.gov · NCT00736229 · Registry updated: 2014-11-20

Condition / research focus: Hyperglycemia; Acute Coronary Syndromes; Myocardial Infarction
Sponsor: Saint Luke's Health System
Countries with listed sites: United States
Registry dates and results: Start: 2008-08. Completion: 2012-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

Mid America Heart Institute Saint Luke's Health System
Kansas City, Missouri, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Exenatide in Extreme Pediatric Obesity

ClinicalTrials.gov · NCT01237197 · Registry updated: 2014-09-12

Condition / research focus: Obesity
Sponsor: University of Minnesota
Countries with listed sites: United States
Registry dates and results: Start: 2010-10. Completion: 2012-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Placebo (drug) — also listed as: Sugar pill

Where the study takes place — 2 listed sites

University of Minnesota
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Children's Hospitals and Clinics of Minnesota
Saint Paul, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Glucagon-like Peptide (GLP) Utilization and Safety

ClinicalTrials.gov · NCT01767389 · Registry updated: 2014-08-04

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: GlaxoSmithKline
Countries with listed sites: No country reported
Registry dates and results: Start: 2012-09. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

The GLP-1 receptor agonist users (other)
DPP-4 inhibitor users (other)
Other ADA users (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine

ClinicalTrials.gov · NCT01602913 · Registry updated: 2014-07-02

Condition / research focus: Depression, Postpartum
Sponsor: GlaxoSmithKline
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-12. Completion: 2012-05 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pravastatin alone (drug)
Paroxetine alone (drug)
Pravastatin and paroxetine combined (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

ClinicalTrials.gov · NCT01181986 · Registry updated: 2014-05-20

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Carl T. Hayden VA Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2010-08. Completion: 2012-12 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide SC (drug) — also listed as: Byetta, exendin-4
Exenatide IV (drug) — also listed as: exendin-4, Byetta
Placebo SC (drug) — also listed as: placebo
Exendin-9 (drug) — also listed as: exendin-(9-39)
Placebo IV (drug) — also listed as: placebo

Where the study takes place — 1 listed sites

Phoenix VA Medical Center
Phoenix, Arizona, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

ClinicalTrials.gov · NCT02129985 · Registry updated: 2014-05-02

Condition / research focus: Type 2 Diabetes
Sponsor: xiaolong zhao
Countries with listed sites: China
Registry dates and results: Start: 2014-02. Completion: 2015-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: GLP-1 receptor agonist
Metformin (drug) — also listed as: Glucophage

Where the study takes place — 1 listed sites

Xiaolong Zhao
Jingan, Shanghai Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →